Why does compounded tirzepatide potency vary between pharmacies?

I have the plan documents and the written criteria, which took two calls to obtain.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

Can someone derive this rather than assert it?

The honest answer is that a well-run compounding pharmacy is a serious operation and that the variance across facilities is wide.

Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.

The relevant detail is that a compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.

A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.

Check the beyond-use date and what it was based on.

Answering this needs the jurisdiction, since the framework differs substantially between countries and even between states.

Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.

Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.

Nothing here is medical advice.

Compounded means unapproved by definition. That is structural, not pejorative.

The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.

Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.

Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.

Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.

The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.

Ask for the certificate of analysis on the lot. A serious facility has one.

The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.

Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.

Facility quality is the dominant variable and cannot be assessed from a website.

The framework is jurisdiction-specific. Check yours rather than a general answer.

This is an area where the legal position and the quality question are separate and both matter.

Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.

Beyond-use dating for compounded sterile preparations is governed by published standards keyed to the compounding environment.

The caveat is jurisdictional. Almost everything in this area is specific to a country and often to a sub-national jurisdiction, and a confident answer that does not name a jurisdiction should be treated as describing somewhere else.

Ask which salt form. A different salt is a different active moiety.